Shots:  

• Henlius to receives $27M up front- ~$13M regulatory milestones- $25M commercial milestones for every $500M of cumulative net sales- and is eligible to receive royalty up to 50% profit of HLX02. If the cumulative net sales of HLX02 reaches $3B- Henlius to receive ~$150M as commercial milestones
• Accord to get an exclusive license to develop and commercialize HLX02 in the US & Canada. The development process strictly followed the EMA and NMPA’s biosimilar guidelines
• In 2018- the companies enter into a license agreement- under which Henlius granted Accord UK exclusive commercialization rights of HLX02 in the EU- the Middle East- North Africa- and the Commonwealth of Independent States. The therapy received EC’s and the NMPA approval sin July & Aug’2020- making it the first China-developed mAb biosimilar approved both in China and in the EU

­ Ref: Henlius | Image: New Scientist